🇺🇸 FDA

Company profile · Sponsor

Fondazione

Fondazione Telethon ETS

E237119 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Fondazione (E237119) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E237119
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN , PEMBROLIZUMAB, CARBOPLATIN , PACLITAXEL , PEMETREXED

    Fondazione

    metastatic NSCLC patients

    phase 3 small molecule active

    1 trial

  2. BEVACIZUMAB, ERLOTINIB

    Fondazione

    Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. Beyfortus 100 mg solution for injection in pre-filled syringe, Beyfortus 50 mg solution for injection in pre-filled syringe, Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)

    Fondazione

    Respiratory Syncytial Virus (RSV)

    phase 3 small molecule active

    1 trial

  4. CAPECITABINE , METFORMIN , ACETYLSALICYLIC ACID , OXALIPLATIN

    Fondazione

    Locally advanced stage II/III rectal cancer

    phase 3 small molecule active

    1 trial

  5. COLECALCIFEROL , PREDNISONE

    Fondazione

    Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  6. DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN

    Fondazione

    Favorable-intermediate-risk Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  7. Dovato 50 mg/300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Combivir 150 mg/300 mg film-coated tablets, Epivir 300 mg film-coated tablets, Ziagen 300 mg film-coated tablets, Retrovir 250 mg capsules, hard, Kivexa 600 mg/300 mg film-coated tablets, Triumeq 50 mg/600 mg/300 mg film-coated tablets

    Fondazione

    HIV-infected

    phase 3 small molecule active

    1 trial

  8. FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA

    Fondazione

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  9. LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CYTARABINE, METHOTREXATE, CYTARABINE, PREDNISONE, METHOTREXATE, Melphalan 50 mg powder and solvent for solution for injection/infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, Idarubicina Sandoz 1 mg/ml concentrato per soluzione per infusione, METHOTREXATE, PREDNISONE, FILGRASTIM, Glivec 100 mg hard capsules, CYTARABINE, PURINETHOL 50 mg compresse, Dexamethasone Phosphate 4 mg/ml Solution for Injection, Keppra 250 mg film-coated tablets, ME

    Fondazione

    Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    phase 3 small molecule active

    1 trial

  10. Levotiroxina Teva 25 microgrammi compresse

    Fondazione

    Hodgkin and non Hodgkin lymphoma, Medulloblastoma

    phase 3 small molecule active

    1 trial

  11. Lynparza 150 mg film-coated tablets, PACLITAXEL , CARBOPLATIN , GEMCITABINE , DOXORUBICIN , Lynparza 100 mg film-coated tablets, CISPLATIN , BEVACIZUMAB

    Fondazione

    Recurrent ovarian cancer

    phase 3 small molecule active

    1 trial

  12. MIDOSTAURIN, ARACYTIN 500 mg/10 ml Polvere e Solvente per Soluzione Iniettabile, DAUNORUBICIN HYDROCHLORIDE

    Fondazione

    Acute Myeloid Leukemia (LMA) with FLT3 mutation

    phase 3 small molecule active

    1 trial

  13. Neuraceq 300 MBq/mL solution for injection

    Fondazione

    cardiac amyloidosis

    phase 3 small molecule active

    1 trial

  14. OTL-103, OTL-103

    Fondazione

    Wiskott-Aldrich syndrome (WAS)

    phase 3 small molecule active

    1 trial

  15. PANITUMUMAB, CAPECITABINE, CAPECITABINE, DISODIUM LEVOFOLINATE, CALCIUM LEVOFOLINATE, FLUOROURACIL, NIVOLUMAB, TEMOZOLOMIDE, FOLINIC ACID, TRASTUZUMAB, TEMOZOLOMIDE, PERTUZUMAB, TEMOZOLOMIDE, OXALIPLATIN, IPILIMUMAB, IRINOTECAN

    Fondazione

    Colon cancer

    phase 3 small molecule active

    1 trial

  16. PREDNISONE, DAPAGLIFLOZIN, RAMIPRIL , SOLU MEDROL 1000 mg/15,6 ml polvere e solvente per soluzione iniettabile, LOSARTAN

    Fondazione

    Idiopathic IgA nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  17. PREDNISONE, DOXORUBICIN , BENDAMUSTINE , VINCRISTINE , VINCRISTINE, CYCLOPHOSPHAMIDE , OBINUTUZUMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, BENDAMUSTINE, RITUXIMAB, PREDNISONE , RITUXIMAB, OBINUTUZUMAB

    Fondazione

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  18. PREDNISONE, PREDNISONE, SODIUM CHLORIDE, RITUXIMAB

    Fondazione

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  19. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection

    Fondazione

    Invasive Breast Cancer

    phase 3 small molecule active

    1 trial

  20. RITUXIMAB, LENALIDOMIDE , RITUXIMAB, RITUXIMAB, RITUXIMAB

    Fondazione

    Follicular lymphoma

    phase 3 small molecule active

    1 trial

  21. RITUXIMAB, PLERIXAFOR, OTL-103, FLUDARABINE PHOSPHATE, LENOGRASTIM, BUSULFAN

    Fondazione

    Wiskott-Aldrich Syndrome

    phase 3 small molecule active

    1 trial

  22. Revlimid 2.5 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 25 mg hard capsules, SOLDESAM 0,2% gocce orali, soluzione, Kyprolis 60 mg powder for solution for infusion

    Fondazione

    PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

    phase 3 small molecule active

    1 trial

  23. TOPOTECAN , DOSTARLIMAB , BEVACIZUMAB , PACLITAXEL , NIRAPARIB , DOXORUBICIN , GEMCITABINE

    Fondazione

    Recurrent ovarian, fallopian tube or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  24. The placebo product consists of a soft capsule similar to the ones containing the active substance, VESSEL® 250 ULS capsule molli

    Fondazione

    Prevention of recurrence after a first episode of Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Fondazione?

Fondazione (E237119) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Fondazione sponsor?

We track 24 ClinicalTrials.gov-linked programs for Fondazione, including Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN , PEMBROLIZUMAB, CARBOPLATIN , PACLITAXEL , PEMETREXED and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Fondazione company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.